Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Immunodeficiency: later-stage trial registry
4 of 5 indexed Primary Immunodeficiency trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Primary Immunodeficiency: 5 US clinical trials tracked, 4 recruiting.
Primary Immunodeficiency is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.
Enrollment posture brief
Registry condition primary-immunodeficiency
OPEN 4 | RECR 80% | LATE 2 | EARLY 0 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Primary Immunodeficiency lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Immunodeficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Immunodeficiency is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Immunodeficiency research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Typical Primary Immunodeficiency enrolment sits around 300 participants.
Median target enrolment is 300 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Primary Immunodeficiency research leans observational.
2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
NIAID Centralized Sequencing Protocol
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03206099
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03610802
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04864886
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
CSL Behring
NCT07076446
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Bio Products Laboratory
NCT00278954
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Immunodeficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Immunodeficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Immunodeficiency page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Primary Immunodeficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Primary Immunodeficiency trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immunodeficiency condition card totals 5 registered trials; most-linked intervention Gammaplex (Intravenous immunoglobulin); top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.